Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
AuteursTurner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romaní S, O'Shaughnessy J
Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma.
Auteursvan der Weyden L, Del Castillo Velasco-Herrera M, Cheema S, Wong K, Boccacino JM, Offord V, Droop A, Jones DRA, Vermes I, Anderson E, Hardy C, de Saint Aubain N, Ferguson PM, Clarke EL, Merchant W, Mogler C, Frew D, Harms PW, Monteagudo C, Billings SD, Arends MJ, Ferreira I, Brenn T, J Adams D
Stress granules are not present in Kras mutant cancers and do not control tumor growth.
AuteursLibert M, Quiquempoix S, Fain JS, Pyr Dit Ruys S, Haidar M, Wulleman M, Herinckx G, Vertommen D, Bouchart C, Arsenijevic T, Van Laethem JL, Jacquemin P
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].
Auteursde Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.
AuteursThomas A, Mayer EL, DeMichele A, Harbeck N, Curigliano G, Ignatiadis M, Adam V, Zhou Y, Brown TP, Gilham L, Chua BH, Kalinsky K, Wolff AC, O'Reilly S
